Trial Profile
Post Market Surveillance of OZURDEX for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Retinal oedema; Retinal vein occlusion
- Focus Therapeutic Use
- Sponsors Allergan
- 28 Jan 2014 New trial record